Abuzzahab F S, Merwin G E, Zimmermann R L, Sherman M C
Pharmakopsychiatr Neuropsychopharmakol. 1977 Mar;10(2):49-56. doi: 10.1055/s-0028-1094519.
Fifty-six hospitalized geriatric patients between the ages of 65 and 80 were given piracetam (Nootropil) 2400 mg/day or placebo on a double blind basis over a two month period. Every patient submitted to a battery of psychological tests before and after the two month trial. These tests included the Similarities, Vocabulary, Digit Symbol, and Block Design subtests of the Wechsler Adult Intelligence Scale; Graham Kendall Memory for Design; Benton Visual Retention; Hooper Visual Organization; Raven Colored Progressive Matrices A, AB, and B; Wechsler Memory Scale A and B; Porteus Maze and Finger Tapping. Patients who were unable to complete this battery were not included in this investigation. In addition, at pretreatment, 4 and 8 weeks, the patient completed a Profiles of Mood States, a Clinical Global Evaluation was done by the investigator, and laboratory determinations were performed. Fifty Patients completed the investigation (25 piracetam, 25 placebo). There were no significant statistical differences between the two groups of patients on all measures utilized except for the Clinical Global Evaluation, where 52% of the patients on piracetam showed minimal improvement versus 25% of the placebo group (P less than 0.05).
56名年龄在65至80岁之间的住院老年患者在两个月的时间里接受了双盲试验,一组每天服用2400毫克吡拉西坦(脑复康),另一组服用安慰剂。在为期两个月的试验前后,每位患者都接受了一系列心理测试。这些测试包括韦氏成人智力量表的相似性、词汇、数字符号和积木图案分测验;格雷厄姆·肯德尔图案记忆测验;本顿视觉保持测验;胡珀视觉组织测验;瑞文彩色渐进矩阵测验A、AB和B;韦氏记忆量表A和B;波特斯迷宫测验和手指敲击测验。无法完成这一系列测试的患者未纳入本研究。此外,在治疗前、治疗4周和8周时,患者完成了情绪状态剖面图,研究者进行了临床整体评估,并进行了实验室检测。50名患者完成了研究(25名服用吡拉西坦,25名服用安慰剂)。除临床整体评估外,两组患者在所有使用的测量指标上均无显著统计学差异,服用吡拉西坦的患者中有52%显示出轻微改善,而安慰剂组为25%(P小于0.05)。